Literature DB >> 20383551

Antibody responses in patients with invasive Staphylococcus aureus infections.

G Jacobsson1, P Colque-Navarro, E Gustafsson, R Andersson, R Möllby.   

Abstract

Correlation between antibody response and clinical outcome in Staphylococcus aureus bacteremia has yielded conflicting results. Immunization schedules have failed in clinical trials. Is the humoral response toward S. aureus of protective nature? A prospective study was performed in patients with invasive S. aureus (ISA) infections during the period 2003-2005. The antibody levels were determined at the beginning and at the end of treatment and one month later (n = 96, n = 71, and n = 51, respectively). As controls, 115 healthy individuals were used. A quantitative enzyme-linked immunosorbent assay (ELISA) against eight purified antigens was performed. Bacterial isolates were grouped as to the production of alpha-toxin, agr type, and pulsed-field gel electrophoresis (PFGE) type. Large variations were seen in the antibody levels. The levels in the second sample were the highest. A correlation between agr group, PFGE group, alpha-toxin production, and initial antibody levels was observed. Patients with fatal outcome displayed lower initial antibody levels to all antigens and significantly so in regard to teichoic acid, lipase, enterotoxin A, and scalded skin syndrome toxin. In episodes with complicated bacteremia, initial significantly low levels to teichoic acid and lipase were registered. Low initial antibody levels against several antigens were associated with increased mortality and complicated bacteremia in invasive S. aureus infections. Bacterial properties, strain, and toxin production affected the antibody response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383551     DOI: 10.1007/s10096-010-0919-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  40 in total

1.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.

Authors:  Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 2.  Immune evasion by staphylococci.

Authors:  Timothy J Foster
Journal:  Nat Rev Microbiol       Date:  2005-12       Impact factor: 60.633

3.  Pediatric antibody response to community-acquired Staphylococcus aureus infection is directed to Panton-Valentine leukocidin.

Authors:  Eric L Brown; M Gabriela Bowden; Rebecca S Bryson; Kristina G Hulten; Andrea S Bordt; Andrea Forbes; Sheldon L Kaplan
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

4.  Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity.

Authors:  I M Nilsson; M Verdrengh; R G Ulrich; S Bavari; A Tarkowski
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

5.  Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.

Authors:  Andrea E Hall; Paul J Domanski; Pratiksha R Patel; John H Vernachio; Peter J Syribeys; Elena L Gorovits; Michael A Johnson; Julia M Ross; Jeff T Hutchins; Joseph M Patti
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 6.  Cytokine induction by Gram-positive bacteria.

Authors:  Christian Draing; Stefanie Sigel; Susanne Deininger; Stephanie Traub; Rebekka Munke; Christoph Mayer; Lars Hareng; Thomas Hartung; Sonja von Aulock; Corinna Hermann
Journal:  Immunobiology       Date:  2008-02-19       Impact factor: 3.144

Review 7.  Staphylococcal vaccines and immunotherapies.

Authors:  Adam C Schaffer; Jean C Lee
Journal:  Infect Dis Clin North Am       Date:  2009-03       Impact factor: 5.982

8.  Differential immunostimulatory effects of Gram-positive bacteria due to their lipoteichoic acids.

Authors:  Young Hee Ryu; Jung Eun Baik; Jae Seung Yang; Seok-Seong Kang; Jintaek Im; Cheol-Heui Yun; Dong Wook Kim; Kangseok Lee; Dae Kyun Chung; Hyang Ran Ju; Seung Hyun Han
Journal:  Int Immunopharmacol       Date:  2008-11-14       Impact factor: 4.932

9.  Comparison of traditional and molecular methods of typing isolates of Staphylococcus aureus.

Authors:  F C Tenover; R Arbeit; G Archer; J Biddle; S Byrne; R Goering; G Hancock; G A Hébert; B Hill; R Hollis
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

Review 10.  The adhesive and immunomodulating properties of the multifunctional Staphylococcus aureus protein Eap.

Authors:  Niamh Harraghy; Muzaffar Hussain; Axana Haggar; Triantafyllos Chavakis; Bhanu Sinha; Mathias Herrmann; Jan-Ingmar Flock
Journal:  Microbiology       Date:  2003-10       Impact factor: 2.777

View more
  27 in total

Review 1.  The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.

Authors:  Gordon Y C Cheung; Michael Otto
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

2.  Levels of antibody against 11 Staphylococcus aureus antigens in a healthy population.

Authors:  Patricia Colque-Navarro; Gunnar Jacobsson; Rune Andersson; Jan-Ingmar Flock; Roland Möllby
Journal:  Clin Vaccine Immunol       Date:  2010-05-05

3.  Staphylococcus saprophyticus surface-associated protein (Ssp) is associated with lifespan reduction in Caenorhabditis elegans.

Authors:  Florian Szabados; Amelie Mohner; Britta Kleine; Sören G Gatermann
Journal:  Virulence       Date:  2013-08-06       Impact factor: 5.882

4.  Differences in humoral immune response between patients with or without nasal carriage of Staphylococcus aureus.

Authors:  H Ghasemzadeh-Moghaddam; W van Wamel; A van Belkum; R A Hamat; V K Neela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-04       Impact factor: 3.267

Review 5.  Will there ever be a universal Staphylococcus aureus vaccine?

Authors:  Gerald B Pier
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

Review 6.  Recurrent infections and immune evasion strategies of Staphylococcus aureus.

Authors:  Hwan Keun Kim; Vilasack Thammavongsa; Olaf Schneewind; Dominique Missiakas
Journal:  Curr Opin Microbiol       Date:  2011-11-14       Impact factor: 7.934

7.  Staphylococcus aureus Protein A Disrupts Immunity Mediated by Long-Lived Plasma Cells.

Authors:  Amanda B Keener; Lance T Thurlow; SunAh Kang; Nicholas A Spidale; Stephen H Clarke; Kenji M Cunnion; Roland Tisch; Anthony R Richardson; Barbara J Vilen
Journal:  J Immunol       Date:  2016-12-28       Impact factor: 5.422

8.  Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations.

Authors:  Yuling Wu; Xu Liu; Ahmad Akhgar; Jia J Li; Hoyin Mok; Bret R Sellman; Li Yu; Lorin K Roskos; Mark T Esser; Alexey Ruzin
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

9.  sarA-mediated repression of protease production plays a key role in the pathogenesis of Staphylococcus aureus USA300 isolates.

Authors:  Agnieszka K Zielinska; Karen E Beenken; Lara N Mrak; Horace J Spencer; Ginell R Post; Robert A Skinner; Alan J Tackett; Alexander R Horswill; Mark S Smeltzer
Journal:  Mol Microbiol       Date:  2012-10-17       Impact factor: 3.501

Review 10.  Staphylococcus aureus bloodstream infections: pathogenesis and regulatory mechanisms.

Authors:  Jakub M Kwiecinski; Alexander R Horswill
Journal:  Curr Opin Microbiol       Date:  2020-03-12       Impact factor: 7.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.